Interferon gamma (IFN-γ) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription by Li, Ping et al.
Interferon gamma (IFN-c) disrupts energy
expenditure and metabolic homeostasis
by suppressing SIRT1 transcription
Ping Li
1,6, Yuhao Zhao
1,6, Xiaoyan Wu
2,6, Minjie Xia
1, Mingming Fang
1,4,
Yasumasa Iwasaki
5, Jiahao Sha
1, Qi Chen
1, Yong Xu
1,* and Aiguo Shen
3,*
1State Key Laboratory of Reproductive Medicine and Department of Pathophysiology, Key Laboratory of
Cardiovascular Disease,
2Laboratory Center for Basic Medical Sciences,
3Institute of Gerontology, The Second
Affiliated Hospital, Nanjing Medical University, Nanjing, China,
4Jiangsu Jiankang Vocational Institute, Nanjing,
China and
5Health Care Center, Kochi University, Kochi, Japan
Received August 10, 2011; Revised September 30, 2011; Accepted October 17, 2011
ABSTRACT
Chronic inflammation impairs metabolic homeosta-
sis and is intimately correlated with the pathogen-
esis of type 2 diabetes. The pro-inflammatory
cytokine IFN-c is an integral part of the metabolic
inflammation circuit and contributes significantly
to metabolic dysfunction. The underlying mechan-
ism, however, remains largely unknown. In the
present study, we report that IFN-c disrupts the ex-
pression of genes key to cellular metabolism and
energy expenditure by repressing the expression
and activity of SIRT1 at the transcription level.
Further analysis reveals that IFN-c requires class II
transactivator (CIITA) to repress SIRT1 transcrip-
tion. CIITA, once induced by IFN-c, is recruited to
the SIRT1 promoter by hypermethylated in cancer
1 (HIC1) and promotes down-regulation of SIRT1
transcription via active deacetylation of core
histones surrounding the SIRT1 proximal promoter.
Silencing CIITA or HIC1 restores SIRT1 activity and
expression of metabolic genes in skeletal muscle
cells challenged with IFN-c. Therefore, our data
delineate an IFN-c/HIC1/CIITA axis that contrib-
utes to metabolic dysfunction by suppressing
SIRT1 transcription in skeletal muscle cells and
as such shed new light on the development of
novel therapeutic strategies against type 2
diabetes.
INTRODUCTION
Type 2 diabetes is characterized by the loss of response to
insulin in peripheral organs including the skeletal muscle
leading up to centric obesity. Animal studies have
correlated type 2 diabetes with impaired mitochondrion
biogenesis, defective oxidative phosphorylation and di-
minished synthesis of proteins involved in energy expend-
iture (1,2). Human epidemiology surveys also reveal a
signiﬁcant mitochondrial dysfunction with reduced
energy consumption (3,4).
Energy expenditure is intricately programmed by the
coordinate action of a network of transcriptional modu-
lators in vivo; dysregulation of this process results in mito-
chondrial defect in the skeletal muscle and ultimately type
2 diabetes (5,6). FOXO1 is considered one of the master
regulators of mitochondrion-dependent energy consump-
tion (7). Nutrient withdrawal activates FOXO1, which in
turn drives the transcription activation of several key
genes involved in fatty acid oxidation, mitochondrial bio-
synthesis and oxidative phosphorylation such as pdk4,
mcad, ppargc-1a and cycs (8). FOXO1 activity is tightly
controlled post-translationally by posphorylation and
acetylation. Importantly, deacetylation of FOXO1 by
the class III deacetylase SIRT1 has been demonstrated
to enhance its nuclear enrichment and target promoter
binding (9,10). In addition, hypoacetylated FOXO1
mimics the effect of SIRT1 over-expression in adipocyte,
suggesting the FOXO1 is a primary target of SIRT1 in
balancing metabolic homeostasis (11).
SIRT1 is the mammalian ortholog of the yeast protein
sir2 that links calorie restriction (CR) to longevity (12).
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energy sensor by deacetylating a range of transcriptional
modulators including FOXOs, peroxisome proliferator
activated receptors (PPARs), liver X receptor (LXR)
and PPAR coactivator 1 alpha (PGC-1a) (13). Notably,
expression and/or activity of SIRT1 are altered during
metabolic disorders. For instance, SIRT1 messages correl-
ate with insulin sensitivity in patients with hyperglycemia
whereas high levels of glucose and fatty acids are syn-
onymous with low SIRT1 expression in cells (14,15).
Despite these observations and the fact that SIRT1
agonists show potential in the treatment of type 2
diabetes (16), it remains undetermined the exact mechan-
ism whereby SIRT1 expression is regulated.
Mounting evidence connects chronic inﬂammation to
the disruption of cellular metabolism (17). Liu et al.
have recently reported that mast cells contribute to the
pathogenesis of type 2 diabetes by producing the
pro-inﬂammatory cytokine interferon gamma (IFN-g)
(18). Several independent investigations have implicated
IFN-g in a host of disorders associated with mitochondrial
defect. IFN-g, through its downstream mediator JAK/
IRF-1, disturbs the mitochondrial membrane potential
and exacerbates liver injury induced by LPS (19). IFN-g
also desensitizes adipocyte to insulin and blocks the mat-
uration of pre-adipocyte in a JAK1/STAT1 dependent
manner (20). Here we report that IFN-g down-regulates
SIRT1 transcription and impairs energy expenditure
in skeletal muscle cells by inducing the transcriptional
modulators class II transactivator (CIITA) and
hypermethylated in cancer 1 (HIC1). Our data highlight
a previously unknown function for CIITA/HIC1 complex
and provide novel insight into the pathogenesis of type 2
diabetes.
MATERIALS AND METHODS
Cell culture and treatment
HEK293, C2C12 and IMR-90 cells were grown in DMEM
supplemented with 10% FBS. Cells were treated with
human or murine recombinant IFN-g (100U/ml, R&D),
nicotinamide (10mM, Sigma), sirtinol (10mM, Sigma), or
TSA (100nM, Sigma) for 12–36h as indicated.
Plasmids, transient transfection and luciferase assay
FLAG-tagged CIITA (21), GFP-tagged HIC1 (22) and
the promoter–luciferase constructs for the SIRT1, mcad,
ppargc-1a, cytc, cpt1 and cox4 genes (23–27) have been
described previously. Silencing of CIITA and HIC1 were
mediated by small interfering RNA (siRNA) using the
following sequences: for murine Ciita, #1: 50-CUGGCA
CAGUGCAAUGAAATT-30 and #2: 50-GAGUGAUAC
AAUGGCAUUATT-30; for human CIITA, 50 UCUCCA
GUAUAUUCAUCUATT-30; for murine Hic1, 50-GUCC
CUUUGUAUAUUCUCUTT-30; for human HIC1, 50-U
GAAGCGGACAUUUUACUUTT-30. Transient trans-
fections were performed with Lipofectamine 2000
(Invitrogen). Luciferase activities were assayed 24–48h
after transfection using a luciferase reporter assay system
(Promega). Experiments were routinely performed in trip-
licate wells and repeated three times.
Protein extraction, immunoprecipitation and western blot
Whole-cell lysates were obtained by re-suspending cell
pellets in RIPA buffer (50mM Tris pH7.4, 150mM
NaCl, 1% Triton X-100) with freshly added protease in-
hibitor (Roche). Nuclear proteins were extracted essen-
tially as described before (28). Speciﬁc antibodies or
pre-immune IgGs (P.I.I.) were added to and incubated
with cell lysate overnight before being absorbed by
Protein A/G-plus Agarose beads. Precipitated immune
complex was released by boiling with 1  SDS electrophor-
esis sample buffer. Alternatively, FLAG-conjugated beads
(M2, Sigma) were added to and incubated with lysates
overnight. Precipitated immune complex was eluted with
3  FLAG peptide (Sigma). Western blot analyses were
performed with anti-FLAG, anti-GFP, anti-b-actin
(Sigma), anti-acetyl lysine (Cell Signaling), anti-CIITA,
anti-HIC1, anti-Brg1 and anti-SIRT1 (Santa Cruz)
antibodies.
RNA isolation and real-time PCR
RNA was extracted with the RNeasy RNA isolation kit
(Qiagen). Reverse transcriptase reactions were performed
using a SuperScript First-strand Synthesis System
(Invitrogen). Real-time PCR reactions were performed
on an ABI Prism 7500 system. Primers and Taqman
probes used for real-time reactions were purchased from
Applied Biosystems.
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) assays were per-
formed essentially as described before (28). In brief, chro-
matin in control and treated cells were cross-linked with
1% formaldehyde. Cells were incubated in lysis buffer
(150mM NaCl, 25mM Tris pH 7.5, 1% Triton X-100,
0.1% SDS, 0.5% deoxycholate) supplemented with
protease inhibitor tablet and PMSF. DNA was frag-
mented into  500-bp pieces using a Branson 250
sonicator. Aliquots of lysates containing 200mgo f
protein were used for each immunoprecipitation reaction
with anti-CIITA, anti-HIC1 (Santa Cruz), anti-acetyl
histone H3, anti-acetyl histone H4 (Millipore), or
pre-immune IgG. Precipitated genomic DNA was
ampliﬁed by real-time PCR with primers surrounding
the murine Sirt1 proximal promoter: forward, 50-GCCA
TCGCAAACTTGAACCACC-30 and reverse, 50-CGTCC
GCCATCTTCCAACTGC-30.
SIRT1 activity assay
Cells were treated with or without IFN-g for 24h.
Whole-cell proteins were isolated with the NETN buffer
(20mM Tris pH 8.0, 100mM NaCl, 1mM EDTA, 0.5%
NP-40) with freshly added protease inhibitor tablet and
SIRT1 activities were measured with a SIRT1 assay kit
(Sigma) according to vender’s recommendations.
1610 Nucleic Acids Research, 2012,Vol.40, No. 4Statistical analysis
One-way ANOVA with post hoc Scheffe analyses were
performed using an SPSS package. P<0.05 were con-
sidered statistically signiﬁcant (asterisks).
RESULTS
IFN-c disrupts metabolic homeostasis
Mast cell-derived IFN-g triggers inﬂammatory responses
and contributes to the pathogenesis of type 2 diabetes (18).
In order to probe the effect of IFN-g on metabolic homeo-
stasis, we examined the expression of several key genes
involved in this process in response to IFN-g treatment.
IFN-g signiﬁcantly downregulated mRNA levels of a
series of genes involved in energy metabolism in both
skeletal muscle (C2C12, Figure 1A) and ﬁbroblast cells
(IMR-90, Figure 1B). The down-regulation of message
levels of these genes likely stemmed from decreased tran-
scription as IFN-g directly repressed the promoter
activities of these genes (Figure 1C).
The forkhead transcription factor FOXO1, whose
functionalities among others include transcriptional acti-
vation of the aforementioned genes, is essential in main-
taining the cellular metabolic balance. Therefore, we
examined whether IFN-g could antagonize the overall
FOXO1 dependent transcriptional program. To this end,
a luciferase construct driven by an array of generic
forkhead response elements (FHRE) was introduced into
C2C12 and IMR-90 cells. As shown in Supplementary
Figure S1A, FOXO1 markedly activated luciferase
activity whereas IFN-g repressed both basal and
FOXO1-stimulated activities, implicating IFN-g as a
potent suppressor of FOXO1 mediated transcription.
Transcriptional activity of FOXO1 is regulated by a
range of different post-translational modiﬁcations. It has
been demonstrated that deacetylation of FOXO1 favors
its nuclear accumulation and target occupancy (10),
raising the possibility that IFN-g may affect FOXO1
activity by targeting its acetylation levels. Indeed,
exposure of cells to IFN-g increased FOXO1 acetylation
(Supplementary Figure S1B), decreased nuclear compart-
mentation of FOXO1 (Supplementary Figure S1C), and
impeded FOXO1 recruitment to target promoter as
evidenced by gel shift assay (Supplementary Figure
S1D). Taken together, these data suggest that IFN-g
disrupts metabolic homeostasis in vitro in cultured
skeletal muscle cells.
IFN-c suppresses the expression of SIRT1
SIRT1 is a key mediator of cellular metabolism and
energy expenditure by regulating the acetylation status
of transcription factors involved in this process.
Therefore, we hypothesized that IFN-g might directly
impact the expression and/or activity of SIRT1. As
depicted in Figure 2A and B, both mRNA and protein
levels of SIRT1 were attenuated in the presence of
IFN-g. In contrast, IFN-g did not signiﬁcantly affect
the expression of the acetyltransferase CBP in either
cells (Supplementary Figure S2A). Decreased SIRT1
expression was a direct result of reduced transcription
rate as demonstrated by promoter reporter assay
(Figure 2C). This was, however, not caused by altered
stability of SIRT1 message (Supplementary Figure S2B).
Moreover, IFN-g treatment led to an inhibition of SIRT1
activity (Figure 2D). Collectively, our results indicate that
IFN-g suppresses SIRT1 expression and activity at the
transcriptional level.
IFN-c suppresses SIRT1 transcription through the
induction of CIITA
We have previously demonstrated that CIITA is a key
mediator of several IFN-g-dependent transcriptional
events (29–31). Therefore, we sought to determine
whether repression of SIRT1 transcription by IFN-g
also depends on CIITA. CIITA expression was
markedly stimulated by IFN-g in C2C12 and IMR-90
cells, paralleling the down-regulation of SIRT1 expression
(Figure 3A and B). Decrease of SIRT1 levels by CIITA
likely occurred as a result of transcriptional inhibition of
the SIRT1 promoter since CIITA directly repressed
SIRT1 promoter activity in a dose response manner
(Figure 3C). In accordance with decreased SIRT1 levels,
transcriptional activity of a panel of metabolic genes as
probed in Figure 1 was severely impaired (Figure 3D).
In order to verify whether CIITA is required for
IFN-g-induced repression of SIRT1 transcription, small
interfering RNA (siRNA) targeting CIITA was
employed. Knockdown of CIITA expression by siRNA
attenuated the repression of SIRT1 expression levels
(Figure 4A–C). More importantly, alleviation of SIRT1
repression by CIITA siRNA also normalized SIRT1
activity (Figure 4D). As a result, down-regulation of
genes involved in energy expenditure by IFN-g was
relieved (Figure 4E). In order to verify that alleviation
of repression of metabolic genes by CIITA knockdown
was via restoration of SIRT1 activity, we treated the
cells with two different types of SIRT1 inhibitors, nico-
tinamide (NAM) and sirtinol, in the presence of CIITA
siRNA. As shown in Supplementary Figure S3, treatment
of either SIRT1 inhibitor blocked the effect of CIITA
silencing on the expression of metabolic genes. In aggre-
gate, this line of data suggest that CIITA mediates the
transcriptional repression of SIRT1 by IFN-g.
CIITA is recruited to the SIRT1 promoter by HIC1
In order to tackle the mechanism whereby CIITA
represses the transcription of SIRT1, we used SIRT1
promoter constructs harboring progressive deletions.
CIITA repressed the activities of all the promoter con-
structs equally well and the region putatively targeted by
CIITA was mapped to  115/+58 (Figure 5A). Indeed,
IFN-g stimulated the occupancy of CIITA to this region
of the SIRT1 promoter in ChIP assay (Figure 5B). Close
examination of this region unveiled a conservative binding
site for the sequence-speciﬁc transcription factor
hypermethylated in cancer 1 (HIC1) (32), suggesting that
CIITA may be enlisted by HIC1 via protein-protein inter-
action. To this end, FLAG-tagged CIITA and
GFP-tagged HIC1 were co-expressed in HEK293 cells.
Nucleic Acids Research,2012, Vol.40, No. 4 1611HIC1 was detected in the immune complex along with
CIITA when whole cell lysates were precipitated by
anti-FLAG (Figure 5C). Reciprocal immunoprecipitation
using anti-GFP antibody was able to pull down both
CIITA and HIC1, conﬁrming that these two proteins
formed a complex in vivo. More importantly, CIITA and
HIC1 synergistically suppressed the promoter activity of
SIRT1 (Figure 5D) whereas depletion of HIC1 with
siRNA blocked the recruitment of CIITA to the SIRT1
promoter (Figure 5E). In accordance, repression of
SIRT1 promoter activity by CIITA was attenuated
(Supplementary Figure S4). Together, these data suggest
that CIITA interacts with and is recruited to the SIRT1
promoter by HIC1 to repress SIRT1 transcription.
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Figure 1. IFN-g disrupts metabolic homeostasis in skeletal muscle cells. (A and B) C2C12 (A) or IMR-90 (B) cells were treated with IFN-g. mRNA
levels were measured by real-time qPCR. (C) C2C12 cells were transfected with different promoter luciferase constructs followed by treatment with
IFN-g. Luciferase activities were normalized to protein concentration and GFP ﬂuorescence for transfection efﬁciency and expressed as relative
luciferase unit (RLU).
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necessary for SIRT1 repression
Next, we examined how HIC1 contributed to the
down-regulation of SIRT1 transcription by IFN-g.
IFN-g stimulated both mRNA and protein levels of
HIC1 (Figure 6A and B). More importantly, occupancy
of HIC1 on the SIRT1 proximal promoter was enhanced
by IFN treatment (Figure 6C). On the contrary, siRNA
mediated knockdown of HIC1 alleviated the repression of
SIRT1 mRNA (Figure 6D) and protein (Figure 6E) ex-
pression and normalized SIRT1 activity in C2C12 cells
treated with IFN-g (Supplementary Figure S5A).
Finally, depletion of HIC1 restored expression of genes
involved in energy expenditure in response to IFN-g
(Figure 6F). Similarly, treatment of either SIRT1 inhibitor
blocked the effect of HIC1 silencing on the expression of
metabolic genes, indicating that alleviation of repression
of metabolic genes by HIC1 knockdown was via restor-
ation of SIRT1 activity (Supplementary Figure S5B). In
conclusion, HIC1 is necessary for IFN-g induced repres-
sion of SIRT1 transcription and disruption of metabolic
equilibrium.
Repression of SIRT1 transcription by IFN-c requires
histone deacetylation
CIITA has been reported to actively engage the epigenetic
machinery, histone deacetylases (HDACs) in particular, in
transcriptional repression (30,33). Thus, we set out to de-
termine whether histone deacetylation might be involved
in the repression of SIRT1 transcription by IFN-g.
Twenty-four hours after IFN-g treatment, signiﬁcant
amounts of acetylated histones H3 and H4 were
removed from the proximal SIRT1 promoter region as
shown by ChIP assays (Figure 7A), alluding to a
possible scenario wherein certain HDAC is recruited to
the SIRT1 promoter to actively deacetylate core
histones. Intriguingly, there was a marked restitution of
acetylated core histones once CIITA was silenced by
siRNA (Figure 7A), indicating that enlistment of
HDACs to the SIRT1 promoter relies on CIITA.
Consistently, pre-treatment with trichostatin A (TSA), a
universal inhibitor of class I and II HDACs, relieved
down-regulation of SIRT1 promoter activity by CIITA
(Figure 7B) and IFN-g (Figure 7C). Thus, IFN-g represses
SIRT1 transcription possibly through CIITA-dependent
histone deacetylation of the SIRT1 promoter.
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Figure 2. IFN-g suppresses expression and activity of SIRT1. (A and B) C2C12 and IMR-90 cells were treated with IFN-g and harvested at different
time points as indicated. SIRT1 mRNA (A) and protein (B) levels were measured by real-time qPCR and Western. (C) C2C12 cells were transfected
with a SIRT1 promoter luciferase construct followed with IFN-g treatment of various doses (50U/ml and 100U/ml) for 24h. Promoter and Western
activities were expressed as RLU. (D) C2C12 and IMR-90 cells were treated with IFN-g for 24h and SIRT1 activity was measured as described
under ‘Materials and Methods’ section.
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When challenged with a demanding need for fuel in such
situations as exercising and fasting, skeletal muscle cells
switch to fatty acid oxidation and ramp up oxidative phos-
phorylation with accelerated rate of energy expenditure.
Disruption of metabolic adaptation in skeletal muscle cells
is associated with insulin resistance and type 2 diabetes
(1,3,4). The NAD+ dependent deacetylase SIRT1 has
emerged as a critical coordinator of cellular metabolism
primarily by impacting deacetylation levels and thus
A
C
D
B
Figure 3. CIITA is induced by IFN-g and directly suppresses SIRT1 transcription. (A and B) C2C12 and IMR-90 cells were treated with IFN-g,
harvested at different time points and probed for CIITA mRNA (A) and protein (B) levels with real-time qPCR and Western. (C) C2C12 and
IMR-90 cells were transfected with a SIRT1 promoter luciferase construct with increasing amount of CIITA plasmid. Promoter activities were
expressed as RLU. (D) C2C12 cells were transfected with different promoter luciferase constructs (pdk4, mcad, ppargc-1a, cpt1, cytc and cox4) with
or without CIITA. Luciferase activities were expressed as relative luciferase unit (RLU).
1614 Nucleic Acids Research, 2012,Vol.40, No. 4AB
C
E
D
Figure 4. CIITA is indispensible for IFN-g induced suppression of SIRT1 expression. (A–D) C2C12 and IMR-90 cells were transfected with siRNA
targeting CIITA (siCIITA) or random sequence (SCR) followed by treatment with IFN-g for 36h. mRNA (A and B) and protein (C) levels of SIRT1
were measured by real-time qPCR and Western. Densitometry of SIRT1 blot was normalized to b-actin blot and expressed as relative unit compared
to the control group which is set arbitrarily as 1. SIRT1 activity (D) was measured as described under ‘Materials and Methods’ section. (E) C2C12
and IMR-90 cells were transfected with siCIITA or SCR followed by treatment with IFN-g. mRNA levels of pdk4, mcad, ppargc-1a, cpt1, cytc and
cox4 were measured by qPCR.
Nucleic Acids Research,2012, Vol.40, No. 4 1615ﬁne-tuning the activities of key transcription factors
involved in this process (5,34). We report here that a
CIITA:HIC1 complex is responsible for SIRT1 repression
and impairment of energy homeostasis in vitro in cultured
skeletal muscle cells by IFN-g.
Initially identiﬁed as the master regulator of MHC II
transactivation, the role of CIITA has been greatly
expanded; recent evidence points to a key role for
CIITA in a variety of pathologies including atheroscler-
osis, pulmonary ﬁbrosis, scleroderma and cancer (35).
Based on homology, CIITA can be placed into the
nucleotide-binding leucine-rich repeat (NLR) family of
proteins that form the cytokine-processing inﬂammasome
and constitute an integral part of the innate immune
system, being the only member of this family that
directly regulates transcription (36). Other members, espe-
cially NLRP3, have recently been implicated in the patho-
genesis of a myriad of metabolic disorders (37). In support
of this notion, it has been found that improved glucose
tolerance is associated with a reduction of NLRP3
mRNA in patients with type 2 diabetes (38). Our new
ﬁndings presented here illustrate that CIITA links the
A
B
DE
C
Figure 5. CIITA is recruited to the SIRT1 promoter by HIC1. (A) SIRT1 promoter constructs of various lengths were transfected into C2C12 cells
with or without CIITA. Promoter activities were expressed as RLU. (B) C2C12 cells were treated with IFN-g. Cells were harvested at different time
points after treatment as indicated and ChIP was preformed with anti-CIITA. Data were expressed as fold enrichment. (C) FLAG-tagged CIITA and
GFP-tagged HIC1 were co-transfected into HEK293 cells. Immunoprecipitation assays were performed with anti-FLAG, anti-GFP, or pre-immune
IgG (P.I.I.) as indicated. Eluates were analyzed by western with anti-FLAG or anti-GFP. (D) A SIRT1 promoter luciferase construct was transfected
into C2C12, IMR-90 or HEK293 cells with HIC1 and/or CIITA as indicated. Promoter activities were expressed as RLU. (E) C2C12 cells were
transfected with HIC1 siRNA or scrambled siRNA followed by treatment with IFN-g. ChIP was preformed with anti-CIITA. Data were expressed
as fold enrichment.
1616 Nucleic Acids Research, 2012,Vol.40, No. 4pro-inﬂammatory signal triggered by IFN-g to reduced
SIRT1 transcription and crippled energy expenditure in
skeletal muscle cells, alluding to a decompensatory role
in cellular metabolism and human disease that is shared
within the NLR family members although the underlying
mechanisms differ signiﬁcantly.
HIC1 is considered a tumor suppressor gene frequently
silenced in human cancers (39). SIRT1 remains one of a
handful of direct targets identiﬁed for HIC1 so far (40).
Acting primarily as a transcriptional repressor, HIC1
forges a complex with several co-repressors including
CtBP and NuRD (32,41). A recent investigation by
Zhang et al. reveals a delicate balance between intracellular
energy status and SIRT1 transcription in a HIC1 depend-
ent manner (42); blockade of glycolysis by 2-deoxyglucose
(2-DG) prevents the formation of a HIC1:CtBP complex
on the SIRT1 promoter and relieves SIRT1 repression.
Our data (Figure 5) deﬁne a novel HIC1-binding protein
AB
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DE
Figure 6. HIC1 expression is induced by IFN-g and is necessary for SIRT1 repression. (A and B) C2C12 and IMR-90 cells were treated with IFN-g.
HIC1 mRNA (A) and protein expression (B) was probed by qPCR and Western. (C) C2C12 cells were treated with IFN-g and harvested at indicated
time points. ChIP was preformed with anti-HIC1. Data were expressed as fold enrichment. (D–F) C2C12 cells were transfected with siHIC1 or SCR
followed by treatment with IFN-g for 36h. SIRT1 mRNA (D) and protein (E) levels were evaluated by qPCR and Western. (F) mRNA levels of
pdk4, mcad, ppargc-1a, cpt1, cytc and cox4 were measured by qPCR.
Nucleic Acids Research,2012, Vol.40, No. 4 1617and assign a potential role for the HIC1:CIITA complex in
the pathogenesis of type 2 diabetes. In addition, CIITA
repressed the promoter activity driven by tandem copies
of the HIC1-binding site (HBS, Li,P. and Xu,Y., unpub-
lished observation), indicating that CIITA could indeed
serve as a genuine corepressor for HIC1 in vivo.
Recently, it has been demonstrated that patients with
type 2 diabetes have higher levels of circulating IFN-g
(43). Since both CIITA (Figure 3) and HIC1 (Figure 6)
can be up-regulated by IFN-g in cultured skeletal muscle
cells, it is of great interest to evaluate whether this phenom-
enon can be extrapolated in vivo to human subjects with or
without type 2 diabetes.
Both CIITA and HIC1 are intimately wired to the epi-
genetic machinery for their transcriptional activities
(32,44). Our data suggest that CIITA dependent histone
deacetylation may play a role in IFN-g induced repression
of SIRT1 transcription (Figure 7) although the speciﬁc
HDAC that is responsible for SIRT1 repression remains
elusive. Jin et al. (45) recently reported that aging dampens
SIRT1 transcription in the liver by promoting the binding
of a C/EBPb:HDAC1 complex on the distal SIRT1
promoter, implicating histone deacetylation as a potential
mechanism shared in the repression of SIRT1 transcrip-
tion. Our preliminary experiments showed that
knockdown of HDAC3, but not HDAC1 or HDAC2,
abrogated repression of SIRT1 promoter activity by
IFN-g (Li,P. and Xu,Y., unpublished data). We and
others have previously identiﬁed HDAC1 and HDAC2
as binding partners for CIITA in the downregulation of
MHC II and collagen type I genes, respectively (30,33).
Unlike HDAC1 and HDAC2 that are usually found in
large complexes containing Sin3, HDAC3 is believed to
primarily mediate transcriptional repression by the
nuclear receptor corepressors including NCoR/SMRT
(46). Recently, Lazar and colleagues have reported that
A
D
BC
Figure 7. Repression of SIRT1 transcription by IFN-g requires histone deacetylation. (A) C2C12 cells were transfected with siCIITA or SCR
followed by treatment with IFN-g. ChIP assays were performed with anti-acetyl histones H3 (AcH3) and H4 (AcH4). (B) A SIRT1 promoter
luciferase construct was transfected into C2C12 cells with CIITA followed by treatment with TSA (100nM). Luciferase activities were expressed as
RLU. (C) A SIRT1 promoter luciferase construct was transfected into C2C12 followed by treatment with IFN-g and TSA. Luciferase activities were
expressed as RLU. (D) A schematic model illustrating the mechanism whereby IFN-g may impact metabolic homeostasis of skeletal muscle cells.
HBS, HIC1-binding site; TFs, transcription factors; Ac, acetyl group.
1618 Nucleic Acids Research, 2012,Vol.40, No. 4disruption of HDAC3 activity by over-expressing a
dominant negative form of NCoR in mice enhances
energy expenditure and insulin sensitivity (47). Of note,
class II HDACs, which include HDAC4, 5, 6, 7 and 10,
are enriched and steer physiologically important programs
in skeletal muscle cells (48). In perspective, future investi-
gations should aim at determining the individual class I
and II HDACs that interact with CIITA and/or HIC1 on
the SIRT1 promoter and their relevance in insulin resist-
ance and type 2 diabetes.
In summary, our ﬁndings (Figure 7D) allude to a
scheme wherein upon challenge with IFN-g, CIITA accu-
mulates in the nucleus, is recruited by HIC1 to the HBS on
the proximal SIRT1 promoter, and represses SIRT1 tran-
scription through active histone deacetylation. Reduced
cellular SIRT1 levels lead to a decrease in deacetylation
of certain transcription factors, altering their activities.
Consequently, transcription of a panel of genes that are
involved in energy expenditure is down-regulated.
Eventually, metabolic homeostasis in skeletal muscles is
impaired with ensuing insulin resistance and type 2
diabetes.
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